/UCW/ EAST SETAUKET, NY – Lixte Biotechnology Holdings, Inc. (OTCQB: LIXT) announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, Director of the Hematologic Malignancies and Stem Cell Transplantation Institute, and holds the Francis and Kathleen McNamara Distinguished Chair in Hematology and Hematopoietic Cell Transplantation at the City of Hope National Medical Center in Duarte, California. He is co-editor of Thomas’ Hematopoietic Cell Transplantation, a definitive textbook for clinicians, scientists and health care professionals.
John S. Kovach, M.D., President and CEO of Lixte, commented, “We are delighted to welcome Dr. Stephen J. Forman to Lixte’s Board. Dr. Forman is an internationally recognized leader in preclinical and clinical cancer research. In the past few years, he has expanded his laboratory research to include immunological approaches to cancer. Pharmacological enhancement of patients’ immune responses to their cancers is of special interest to Lixte as the enzyme target of its lead clinical compound, LB-100, has been reported recently to be critical to immune function. Dr. Forman’s judgment and expertise in cancer drug development will prove an invaluable addition to Lixte as we work towards bringing improved treatments of human cancers and other life-threatening diseases to clinical practice.”
About Lixte Biotechnology Holdings, Inc.
Lixte is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then design novel compounds to attack those targets. Lixte’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. Lixte’s unique phosphatase inhibitor, LB-100, is completing a Phase I clinical trial at two NCI designated Comprehensive Cancer Centers and three US Oncology Research sites (see ClinicalTrials.gov: Identifier NCTO1837667).
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company’s financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future product demand, supply, manufacturing, costs, marketing and pricing factors are all forward-looking statements. These statements are generally accompanied by words such as “intend,” anticipate,” “believe,” “estimate,” “potential(ly),” “continue,” “forecast,” “predict,” “plan,” “may,” “will,” “could,” “would,” “should,” “expect” or the negative of such terms or other comparable terminology. The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash, research results, competition from other similar businesses, and market and general economic factors. This discussion should be read in conjunction with the Company’s filings with the United States Securities and Exchange Commission at http://www.sec.gov/edgar.shtml.
Additional information on the Company is available at www.lixte.com.